Patient and Cardiologist Perspectives on the Treatment of Patients With Concomitant ASCVD and Obesity

Document Type

Journal Article

Publication Date

1-1-2025

Journal

Journal of patient experience

Volume

12

DOI

10.1177/23743735251342141

Keywords

ASCVD; antiobesity medications; atherosclerotic cardiovascular disease; bias; cardiology; cardiovascular diseases; ethnic and racial minorities; obesity; obesity management; physician–patient relations

Abstract

Atherosclerotic cardiovascular disease (ASCVD) and obesity pose challenges to patients, healthcare professionals (HCPs), and health systems. The aim of this study was to understand the journey of patients with ASCVD and obesity, their caregivers, and managing HCPs to optimize treatment outcomes. Patients with ASCVD and body mass index ≥ 27 kg/m (N = 61), their caregivers (N = 12), and HCPs (N = 24) were given an online survey and participated in 1:1 interviews. Cardiology HCPs (N = 120) were given a quantitative online survey. Despite the presence of risk factors, patients described little communication or urgency from their HCPs regarding the link between obesity and cardiovascular health prior to an ASCVD event. Cardiology HCPs ranked obesity as only the fourth most important parameter to monitor pre- and post-ASCVD event but were hesitant to prescribe antiobesity medications pre- and post-ASCVD despite new treatment options. In fact, only 12% recommended medication for weight management. Comprehensive HCP training on weight management and medication options as well as training on strategies to communicate these options to patients and involve them in their own treatment decisions may improve patient experiences and lead to improved health outcomes in patients with obesity and ASCVD.

Department

Medicine

Link to Full Text

Share

COinS